Cannabis Compounds May Reverse Liver Disease

Compounds found in cannabis, specifically cannabidiol (CBD) and cannabigerol (CBG), have demonstrated potential in treating metabolic dysfunction-associated steatotic liver disease (MASLD), according to research from the Hebrew University of Jerusalem. Published in the British Journal of Pharmacology, the study found these non-intoxicating compounds significantly reduced liver fat and enhanced metabolic health in experimental settings.

The research identified a process called "metabolic remodeling," where CBD and CBG acted as a "backup battery" for the liver by increasing high-energy molecules. This helped the organ function better under the stress of a high-fat diet. Additionally, these compounds restored the activity of cellular enzymes responsible for breaking down harmful fats and waste.

While CBG showed particularly robust results, including reduced body fat and improved insulin sensitivity, the researchers emphasize that these findings are from controlled experimental environments. Further clinical trials are crucial to determine effective applications for human patients. Experts caution that while promising, cannabis is not a universal panacea, and strong evidence supports its use only for specific, FDA-approved conditions.